Tango Therapeutics, Inc. short interest in 2026
In 2026, Tango Therapeutics, Inc.'s disclosed short interest ran from 31.76% of shares outstanding on 15 Jan 2026 to 24.83% on 15 Sep 2026, a change of -6.93 percentage points. The year's high was 34.95% on 13 Feb 2026 and its low 22.29% on 15 May 2026, averaging 28.66% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.93 days on 14 Aug 2026. Full history: Tango Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 31.76% (15 Jan 2026)
- End of year
- 24.83% (15 Sep 2026)
- Change
- -6.93 pp
- High
- 34.95% (13 Feb 2026)
- Low
- 22.29% (15 May 2026)
- Average
- 28.66%
- Highest days to cover
- 20.93 (14 Aug 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 31.76% | 12.03 | results (8-K) |
| 30 Jan 2026 | 34.04% | 16.78 | |
| 13 Feb 2026 | 34.95% | 16.21 | |
| 27 Feb 2026 | 34.16% | 18.20 | |
| 13 Mar 2026 | 33.11% | 9.77 | 10-K filed, results (8-K) |
| 31 Mar 2026 | 28.29% | 12.09 | |
| 15 Apr 2026 | 28.20% | 14.36 | |
| 30 Apr 2026 | 26.81% | 12.51 | |
| 15 May 2026 | 22.29% | 10.00 | 10-Q filed, results (8-K) |
| 29 May 2026 | 23.47% | 13.01 | |
| 15 Jun 2026 | 23.86% | 5.43 | |
| 30 Jun 2026 | 29.44% | 6.59 | |
| 15 Jul 2026 | 29.94% | 15.32 | |
| 31 Jul 2026 | 31.26% | 19.15 | |
| 14 Aug 2026 | 25.61% | 20.93 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 25.28% | 19.70 | |
| 15 Sep 2026 | 24.83% | 18.76 |
See also: Tango Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.